Elizabeth Faust1, Irina Pivneva2, Karen Yang3, Keith A Betts4, Zubair Ahmed5, Shivang Joshi6, Rebecca Hogan6, Andrew Blumenfeld7, Jack Schim7, Alexander Feoktistov8, Kenneth Carnes9, Mark Bensink10, Eric Q Wu11, Denise E Chou10, David Chandler10. 1. Analysis Group, Inc., 151 W 42nd St, 23rd Floor, New York, NY, 10036, USA. Lizzie.murdoch@analysisgroup.com. 2. Analysis Group, Inc., Montreal, QC, Canada. 3. Analysis Group, Inc., 151 W 42nd St, 23rd Floor, New York, NY, 10036, USA. 4. Analysis Group, Inc., Los Angeles, CA, USA. 5. Center for Neurological Restoration, Cleveland Clinic, Cleveland, OH, USA. 6. DENT Neurologic Institute, Amherst, NY, USA. 7. The Headache Center of Southern California, Carlsbad, CA, USA. 8. Diamond Headache Clinic, Chicago, IL, USA. 9. Raleigh Neurology Associates, Raleigh, NC, USA. 10. Amgen Inc., Thousand Oaks, CA, USA. 11. Analysis Group, Inc., Boston, MA, USA.
Abstract
INTRODUCTION: Erenumab, a first-in-class monoclonal antibody targeting the calcitonin gene-related peptide pathway, was approved by the US Food and Drug Administration in 2018 for the prevention of migraine in adults. There is limited data available on its impact in real-world settings. The study aim was to characterize the real-world treatment profiles, clinical outcomes, and healthcare resource utilization of patients prescribed erenumab from select major US headache centers. METHODS: A retrospective chart review of patients with migraine treated with erenumab for at least 3 months across five major headache centers was conducted. Data was collected from patient charts between April 2019 and April 2020 and included patient and clinical characteristics, migraine medication use, and outpatient visits. The date of the first prescription fill of erenumab was defined as the index date. The baseline period comprised the 3 months prior to the index date and the study period comprised the at least 3 months on erenumab treatment. RESULTS: Data from a total of 1034 patients with chronic migraine with a mean of 9.3 months of erenumab treatment were analyzed. Patients were on average 48 years old, 86% were female, and 79% were white. Patients had a mean of 5 preventive treatment failures prior to erenumab initiation. Patients used a mean of 2 preventive treatments (excluding erenumab) and 2 acute treatments during baseline and study periods. Among patients with effectiveness data, 45% of patients had improvement in physician-reported migraine severity and 35% experienced at least 50% reduction in mean headache/migraine days per month. The average number of monthly outpatient visits was 0.43 and 0.30 before and after erenumab initiation, respectively. CONCLUSION: In this predominantly refractory chronic migraine population treated in select headache centers, patients had fewer headache/migraine days per month and outpatient visits after initiating erenumab. However, patients largely continued to be managed via a polypharmacy approach after erenumab initiation.
INTRODUCTION:Erenumab, a first-in-class monoclonal antibody targeting the calcitonin gene-related peptide pathway, was approved by the US Food and Drug Administration in 2018 for the prevention of migraine in adults. There is limited data available on its impact in real-world settings. The study aim was to characterize the real-world treatment profiles, clinical outcomes, and healthcare resource utilization of patients prescribed erenumab from select major US headache centers. METHODS: A retrospective chart review of patients with migraine treated with erenumab for at least 3 months across five major headache centers was conducted. Data was collected from patient charts between April 2019 and April 2020 and included patient and clinical characteristics, migraine medication use, and outpatient visits. The date of the first prescription fill of erenumab was defined as the index date. The baseline period comprised the 3 months prior to the index date and the study period comprised the at least 3 months on erenumab treatment. RESULTS: Data from a total of 1034 patients with chronic migraine with a mean of 9.3 months of erenumab treatment were analyzed. Patients were on average 48 years old, 86% were female, and 79% were white. Patients had a mean of 5 preventive treatment failures prior to erenumab initiation. Patients used a mean of 2 preventive treatments (excluding erenumab) and 2 acute treatments during baseline and study periods. Among patients with effectiveness data, 45% of patients had improvement in physician-reported migraine severity and 35% experienced at least 50% reduction in mean headache/migraine days per month. The average number of monthly outpatient visits was 0.43 and 0.30 before and after erenumab initiation, respectively. CONCLUSION: In this predominantly refractory chronic migraine population treated in select headache centers, patients had fewer headache/migraine days per month and outpatient visits after initiating erenumab. However, patients largely continued to be managed via a polypharmacy approach after erenumab initiation.
Authors: Maurice T Driessen; Joshua M Cohen; Stephen F Thompson; Oscar Patterson-Lomba; Michael J Seminerio; Karen Carr; Todor I Totev; Rochelle Sun; Erica Yim; Fan Mu; Rajeev Ayyagari Journal: J Headache Pain Date: 2022-05-16 Impact factor: 8.588
Authors: Maurice T Driessen; Joshua M Cohen; Oscar Patterson-Lomba; Stephen F Thompson; Michael Seminerio; Karen Carr; Todor I Totev; Rochelle Sun; Erica Yim; Fan Mu; Rajeev Ayyagari Journal: J Headache Pain Date: 2022-04-11 Impact factor: 7.277